ATE406916T1 - Cephalosporin verbindungen enthaltende zusammensetzungen und deren verwendung zur behandlung von bakteriellen infektionen bei hunden und katzen - Google Patents
Cephalosporin verbindungen enthaltende zusammensetzungen und deren verwendung zur behandlung von bakteriellen infektionen bei hunden und katzenInfo
- Publication number
- ATE406916T1 ATE406916T1 AT02781499T AT02781499T ATE406916T1 AT E406916 T1 ATE406916 T1 AT E406916T1 AT 02781499 T AT02781499 T AT 02781499T AT 02781499 T AT02781499 T AT 02781499T AT E406916 T1 ATE406916 T1 AT E406916T1
- Authority
- AT
- Austria
- Prior art keywords
- cats
- dogs
- compositions containing
- bacterial infections
- treating bacterial
- Prior art date
Links
- 208000035143 Bacterial infection Diseases 0.000 title 1
- -1 CEPHALOSPORIN COMPOUNDS Chemical class 0.000 title 1
- 229930186147 Cephalosporin Natural products 0.000 title 1
- 208000022362 bacterial infectious disease Diseases 0.000 title 1
- 229940124587 cephalosporin Drugs 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
- A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
- A61K31/546—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine containing further heterocyclic rings, e.g. cephalothin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
- A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Dermatology (AREA)
- Communicable Diseases (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Oncology (AREA)
- Inorganic Chemistry (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US33853601P | 2001-11-30 | 2001-11-30 | |
| US39893202P | 2002-07-26 | 2002-07-26 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE406916T1 true ATE406916T1 (de) | 2008-09-15 |
Family
ID=26991236
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT02781499T ATE406916T1 (de) | 2001-11-30 | 2002-11-13 | Cephalosporin verbindungen enthaltende zusammensetzungen und deren verwendung zur behandlung von bakteriellen infektionen bei hunden und katzen |
Country Status (27)
| Country | Link |
|---|---|
| US (1) | US7378408B2 (enExample) |
| EP (1) | EP1448234B1 (enExample) |
| JP (1) | JP4689959B2 (enExample) |
| KR (1) | KR100621291B1 (enExample) |
| CN (1) | CN100502873C (enExample) |
| AR (1) | AR037595A1 (enExample) |
| AT (1) | ATE406916T1 (enExample) |
| AU (1) | AU2002348986B2 (enExample) |
| BR (1) | BRPI0214583B1 (enExample) |
| CA (1) | CA2468708C (enExample) |
| CY (1) | CY1108437T1 (enExample) |
| DE (1) | DE60228749D1 (enExample) |
| DK (1) | DK1448234T3 (enExample) |
| EA (1) | EA008503B1 (enExample) |
| ES (1) | ES2307800T3 (enExample) |
| HR (1) | HRP20040487A2 (enExample) |
| IL (2) | IL161851A0 (enExample) |
| IS (1) | IS7214A (enExample) |
| MA (1) | MA27085A1 (enExample) |
| MX (1) | MXPA04003724A (enExample) |
| NO (1) | NO334818B1 (enExample) |
| NZ (1) | NZ532208A (enExample) |
| PL (1) | PL212683B1 (enExample) |
| PT (1) | PT1448234E (enExample) |
| TN (1) | TNSN04097A1 (enExample) |
| TW (1) | TWI248363B (enExample) |
| WO (1) | WO2003045435A1 (enExample) |
Families Citing this family (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ITMI20021725A1 (it) | 2002-08-01 | 2002-10-31 | Zambon Spa | Composizioni farmaceutiche ad attivita' antibiotica. |
| US20080096858A1 (en) * | 2004-04-22 | 2008-04-24 | University Of Connecticut | Method of Stabilizing Disordered Cefovecin Sodium Salt |
| EP1656930A1 (en) * | 2004-11-10 | 2006-05-17 | Basilea Pharmaceutica AG | Stabilized freeze-dried formulation for cephalosporin derivatives |
| WO2006064516A1 (en) * | 2004-12-17 | 2006-06-22 | Venus Remedies Limited | Antibiotic combinations for providing total solution to the treatment of infections |
| CA2597812C (en) * | 2005-02-14 | 2012-01-24 | Venus Remedies Limited | Parenteral combination therapy for infective conditions with drug resistant bacterium |
| ATE472996T1 (de) * | 2005-10-29 | 2010-07-15 | Intervet Int Bv | Cefquinomzusammensetzungen und verfahren zu ihrer verwendung |
| US20080103121A1 (en) * | 2006-10-30 | 2008-05-01 | Gole Dilip J | Cephalosporin derivative formulation |
| WO2009111422A2 (en) * | 2008-03-04 | 2009-09-11 | Elan Pharmaceuticals, Inc. | Stable liquid formulations of anti-infective agents and adjusted anti-infective agent dosing regimens |
| CN101352422B (zh) * | 2008-09-17 | 2011-04-20 | 厦门朝阳生物工程有限公司 | 河豚毒素冻干粉针制剂及其制备方法 |
| US9060926B2 (en) | 2008-10-31 | 2015-06-23 | The Invention Science Fund I, Llc | Compositions and methods for therapeutic delivery with frozen particles |
| US8849441B2 (en) | 2008-10-31 | 2014-09-30 | The Invention Science Fund I, Llc | Systems, devices, and methods for making or administering frozen particles |
| US8793075B2 (en) | 2008-10-31 | 2014-07-29 | The Invention Science Fund I, Llc | Compositions and methods for therapeutic delivery with frozen particles |
| US9050317B2 (en) | 2008-10-31 | 2015-06-09 | The Invention Science Fund I, Llc | Compositions and methods for therapeutic delivery with frozen particles |
| US8731840B2 (en) | 2008-10-31 | 2014-05-20 | The Invention Science Fund I, Llc | Compositions and methods for therapeutic delivery with frozen particles |
| US9072688B2 (en) | 2008-10-31 | 2015-07-07 | The Invention Science Fund I, Llc | Compositions and methods for therapeutic delivery with frozen particles |
| US20110150765A1 (en) | 2008-10-31 | 2011-06-23 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Frozen compositions and methods for piercing a substrate |
| US9072799B2 (en) | 2008-10-31 | 2015-07-07 | The Invention Science Fund I, Llc | Compositions and methods for surface abrasion with frozen particles |
| US8762067B2 (en) | 2008-10-31 | 2014-06-24 | The Invention Science Fund I, Llc | Methods and systems for ablation or abrasion with frozen particles and comparing tissue surface ablation or abrasion data to clinical outcome data |
| US8725420B2 (en) | 2008-10-31 | 2014-05-13 | The Invention Science Fund I, Llc | Compositions and methods for surface abrasion with frozen particles |
| US8788211B2 (en) * | 2008-10-31 | 2014-07-22 | The Invention Science Fund I, Llc | Method and system for comparing tissue ablation or abrasion data to data related to administration of a frozen particle composition |
| US8545806B2 (en) | 2008-10-31 | 2013-10-01 | The Invention Science Fund I, Llc | Compositions and methods for biological remodeling with frozen particle compositions |
| US8721583B2 (en) | 2008-10-31 | 2014-05-13 | The Invention Science Fund I, Llc | Compositions and methods for surface abrasion with frozen particles |
| US9050251B2 (en) | 2008-10-31 | 2015-06-09 | The Invention Science Fund I, Llc | Compositions and methods for delivery of frozen particle adhesives |
| US9060934B2 (en) | 2008-10-31 | 2015-06-23 | The Invention Science Fund I, Llc | Compositions and methods for surface abrasion with frozen particles |
| US9060931B2 (en) | 2008-10-31 | 2015-06-23 | The Invention Science Fund I, Llc | Compositions and methods for delivery of frozen particle adhesives |
| US8731841B2 (en) | 2008-10-31 | 2014-05-20 | The Invention Science Fund I, Llc | Compositions and methods for therapeutic delivery with frozen particles |
| US9050070B2 (en) | 2008-10-31 | 2015-06-09 | The Invention Science Fund I, Llc | Compositions and methods for surface abrasion with frozen particles |
| US20100111857A1 (en) | 2008-10-31 | 2010-05-06 | Boyden Edward S | Compositions and methods for surface abrasion with frozen particles |
| US20140274993A1 (en) | 2013-03-15 | 2014-09-18 | Cubist Pharmaceuticals, Inc. | Ceftolozane-tazobactam pharmaceutical compositions |
| US9872906B2 (en) | 2013-03-15 | 2018-01-23 | Merck Sharp & Dohme Corp. | Ceftolozane antibiotic compositions |
| US20140274994A1 (en) * | 2013-03-15 | 2014-09-18 | Cubist Pharmaceuticals, Inc. | Stabilizing ceftolozane |
| WO2017007515A1 (en) * | 2015-07-09 | 2017-01-12 | Universal Nutrients, Llc | Pharmaceutical compositions |
| JP7020913B2 (ja) | 2015-09-07 | 2022-02-16 | 持田製薬株式会社 | アルギン酸凍結乾燥製剤 |
| EP3687993A1 (en) | 2017-09-27 | 2020-08-05 | Meiji Seika Pharma Co., Ltd. | Pharmaceutical forms of diazabicyclooctane derivatives and manufacturing method thereof |
| EP3687992A1 (en) | 2017-09-27 | 2020-08-05 | Meiji Seika Pharma Co., Ltd. | Crystalline forms of diazabicyclooctane derivatives and production process thereof |
| CN111447924A (zh) * | 2017-09-27 | 2020-07-24 | 费多拉制药公司 | 二氮杂二环辛烷衍生物的药物形式及其制备方法 |
| GB2575261B (en) | 2018-07-02 | 2022-03-09 | Norbrook Lab Ltd | Intermediates in the synthesis of C3-substituted cephalosporins |
| CN109393004A (zh) * | 2018-09-28 | 2019-03-01 | 上海锦立保鲜科技有限公司 | 一种利用冻品自由水升华实现真空解冻的方法 |
| CN118284438A (zh) * | 2021-11-26 | 2024-07-02 | 安斯泰来制药株式会社 | 含有吲哚菁化合物的固体药物组合物 |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4002748A (en) * | 1976-01-19 | 1977-01-11 | Eli Lilly And Company | Method of preparing sterile essentially amorphous cefazolin for reconstitution for parenteral administration |
| JPS5711909A (en) * | 1980-06-23 | 1982-01-21 | Shionogi & Co Ltd | Stable freeze-dried preparation of beta-lactam |
| JPS6045514A (ja) * | 1983-08-22 | 1985-03-12 | Shionogi & Co Ltd | 安定な抗菌性凍結乾燥製剤 |
| SE8500273D0 (sv) * | 1985-01-22 | 1985-01-22 | Leo Ab | Nya tricykliska foreningar, kompositioner innehallande sadana foreningar, framstellningsforfaranden och behandlingsmetoder |
| US5138066A (en) * | 1987-08-14 | 1992-08-11 | Hoffmann-La Roche, Inc. | Intermediates for cephalosporins with sulfur-containing oxyimino side chain |
| NZ227842A (en) | 1988-02-05 | 1990-12-21 | Lilly Co Eli | Crystalline 2.5-hydrate form of a beta-lactam |
| CA2024587A1 (en) * | 1989-09-05 | 1991-03-06 | Bernard Ecanow | Drug delivery compositions based on biological cells or components thereof and methods |
| US6001997A (en) * | 1990-07-24 | 1999-12-14 | Bateson; John Hargreaves | Cephalosporins and homologues, preparations and pharmaceutical compositions |
| MY106399A (en) * | 1990-07-24 | 1995-05-30 | Pfizer | Cephalosporins and homologeus, preparation and pharmaceutical composition |
| US6020329A (en) * | 1990-07-24 | 2000-02-01 | Pzifer Inc. | Cephaloporins and homologues, preparations and pharmaceutical compositions |
| US5401842A (en) * | 1992-09-08 | 1995-03-28 | Bristol-Myers Squibb Company | Injectable compositions of a cephalosporin dihydrate salt |
| EP0664117A1 (de) * | 1994-01-25 | 1995-07-26 | F. Hoffmann-La Roche Ag | Liposomenlösungen |
| US5665760A (en) * | 1995-09-18 | 1997-09-09 | Sanofi Winthrop, Inc. | Lyophilized thioxanthenone antitumor agents |
| KR100312622B1 (ko) * | 1998-11-03 | 2002-02-28 | 김송배 | 생약을주성분으로한안정화된항암제조성물및그제조방법 |
| JP2001199889A (ja) * | 1999-11-11 | 2001-07-24 | Takeda Chem Ind Ltd | 縮合ピリダジン誘導体を含有してなる点鼻用剤 |
| EP1246668B1 (en) | 1999-12-01 | 2005-11-30 | Natco Pharma Limited | An rapid acting freeze dired oral pharmaceutical composition for treating migraine |
| GB0002835D0 (en) * | 2000-02-09 | 2000-03-29 | Melvin William T | Drug resistance in cancer |
| GB0019124D0 (en) | 2000-08-03 | 2000-09-27 | Pfizer | Novel process |
| RU2237670C1 (ru) * | 2000-12-04 | 2004-10-10 | Пфайзер Продактс Инк. | Способ взаимодействия и промежуточные продукты, пригодные для получения цефалоспоринов |
-
2002
- 2002-11-12 US US10/292,343 patent/US7378408B2/en not_active Expired - Lifetime
- 2002-11-13 EA EA200400489A patent/EA008503B1/ru unknown
- 2002-11-13 NZ NZ532208A patent/NZ532208A/en not_active IP Right Cessation
- 2002-11-13 DE DE60228749T patent/DE60228749D1/de not_active Expired - Lifetime
- 2002-11-13 AT AT02781499T patent/ATE406916T1/de active
- 2002-11-13 WO PCT/IB2002/004743 patent/WO2003045435A1/en not_active Ceased
- 2002-11-13 PL PL370083A patent/PL212683B1/pl unknown
- 2002-11-13 ES ES02781499T patent/ES2307800T3/es not_active Expired - Lifetime
- 2002-11-13 KR KR1020047008097A patent/KR100621291B1/ko not_active Expired - Lifetime
- 2002-11-13 CN CNB028229258A patent/CN100502873C/zh not_active Expired - Lifetime
- 2002-11-13 DK DK02781499T patent/DK1448234T3/da active
- 2002-11-13 CA CA002468708A patent/CA2468708C/en not_active Expired - Lifetime
- 2002-11-13 EP EP02781499A patent/EP1448234B1/en not_active Expired - Lifetime
- 2002-11-13 AU AU2002348986A patent/AU2002348986B2/en not_active Expired
- 2002-11-13 MX MXPA04003724A patent/MXPA04003724A/es active IP Right Grant
- 2002-11-13 HR HR20040487A patent/HRP20040487A2/hr not_active Application Discontinuation
- 2002-11-13 IL IL16185102A patent/IL161851A0/xx unknown
- 2002-11-13 BR BRPI0214583A patent/BRPI0214583B1/pt active IP Right Grant
- 2002-11-13 JP JP2003546936A patent/JP4689959B2/ja not_active Expired - Lifetime
- 2002-11-13 PT PT02781499T patent/PT1448234E/pt unknown
- 2002-11-19 TW TW091133707A patent/TWI248363B/zh not_active IP Right Cessation
- 2002-11-28 AR ARP020104594A patent/AR037595A1/es not_active Application Discontinuation
-
2004
- 2004-04-07 IS IS7214A patent/IS7214A/is unknown
- 2004-05-06 IL IL161851A patent/IL161851A/en active IP Right Grant
- 2004-05-20 MA MA27689A patent/MA27085A1/fr unknown
- 2004-05-28 TN TNP2004000097A patent/TNSN04097A1/fr unknown
- 2004-06-01 NO NO20042271A patent/NO334818B1/no not_active IP Right Cessation
-
2008
- 2008-10-21 CY CY20081101180T patent/CY1108437T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE406916T1 (de) | Cephalosporin verbindungen enthaltende zusammensetzungen und deren verwendung zur behandlung von bakteriellen infektionen bei hunden und katzen | |
| DE60021729D1 (de) | Photosensibilisatoren enthaltende antimikrobielle zusammensetzung, gegenstände und verfahren zur verwendung | |
| ATE547101T1 (de) | Verfahren zur verwendung von diketopiperazinen und zusammensetzungen, die diese enthalten | |
| ATE325614T1 (de) | Milchsäurebakterienkombination und deren verwendung zur behandlung und prävention von infektionen und entzündungen | |
| DE60113301D1 (de) | Gel für die Behandlung von Katzen und Hunden | |
| ATE255888T1 (de) | Tetrahydronaphtalene verbindungen und deren verwendung zur behandlung von neurodegenerativen krankheiten | |
| EP1565230A4 (en) | COMPOSITIONS OF MATERIALS AND ASSOCIATED SYSTEMS AND METHODS FOR THE TREATMENT OF CARDIAC CONDITIONS | |
| DE60204548D1 (de) | Mch antagonisten und deren verwendung zur behandlung von fettleibigkeit | |
| EP1014982A4 (en) | TROGLITAZONE COMPOUNDS FOR THE TREATMENT OF CRITICAL AGE | |
| DE60214080D1 (de) | Medizinische Verwendung thyromimetischer Verbindungen gegen Haarausfall und Zusammensetzungen | |
| NO20025204D0 (no) | Forbindelser og fremgangsmÕter for behandling og forebygging av bakterielle infeksjoner | |
| CY1108640T1 (el) | Χρηση αντισηπτικων δραστικων ουσιων σε ρμμα οστικα τσιμεντα | |
| DE602005017373D1 (de) | Verbindungen zur behandlung von schizophrenie und/oder glucoregulatorische auffälligkeiten | |
| ATE259818T1 (de) | Substituierte tricyclische verbindungen und deren verwendung zur behandlung von spla2-bedingten erkrankungen | |
| EP1468005A4 (en) | METHODS OF USING SACCHARIDE CONJUGATES AND ACETAMIDINE OR GUANIDINE COMPOUNDS FOR THE TREATMENT OF BACTERIAL INFECTIONS | |
| ATE539746T1 (de) | Zusammensetzung zur verbesserung von kognition und gedächtnis | |
| DE60027429D1 (de) | Dihydrobenzodiazepinen und deren verwendung zur behandlung von dyslipidämien | |
| DE60027003D1 (de) | Bakterielles konsortium ebc1000 und verfahren zu dessen verwendung zur behandlung von biologisch schwer abbaubaren toxischen chemikalien in industriellem abwasser, abfällen und böden | |
| ATE528004T1 (de) | Chinolon-antibiotika zur behandlung von periodontaler infektionen | |
| ATE372132T1 (de) | Verfahren zum sterilisieren von gegenständen | |
| DE60125212D1 (de) | Verwendung von Aivlosin zur Behandlung und Prevention der Lawsonia-Infektionen in Schweinen. | |
| DE60325496D1 (de) | Verwendung von dihydroimidazolonen zur behandlung von epilepsie bei hunden | |
| ATE339439T1 (de) | Lineare basische verbindungen mit nk-2 antagonistischer aktivität und deren zusammensetzungen | |
| GB0519962D0 (en) | Composting composition comprising animal urine and agricultural waste and method for vermicomposting the same | |
| EP1233967A4 (en) | PYRIDINONES FOR THE TREATMENT AND PREVENTION OF BACTERIAL INFECTIONS |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |
Ref document number: 1448234 Country of ref document: EP |